Cidara Therapeutics (CDTX) to Release Quarterly Earnings on Thursday

Cidara Therapeutics (NASDAQ:CDTX) is anticipated to issue its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($1.24) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

Cidara Therapeutics (NASDAQ:CDTX) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($1.65) EPS for the quarter, topping the consensus estimate of ($1.87) by $0.22. On average, analysts expect Cidara Therapeutics to post $-9 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Cidara Therapeutics Price Performance

Cidara Therapeutics stock opened at $100.39 on Wednesday. Cidara Therapeutics has a fifty-two week low of $12.74 and a fifty-two week high of $121.21. The firm’s 50 day simple moving average is $87.07 and its 200-day simple moving average is $56.86. The company has a market cap of $2.55 billion, a P/E ratio of -9.02 and a beta of 1.32.

Analyst Upgrades and Downgrades

CDTX has been the topic of several research analyst reports. Royal Bank Of Canada set a $137.00 price objective on shares of Cidara Therapeutics and gave the stock an “outperform” rating in a research report on Wednesday, September 24th. JMP Securities set a $173.00 price target on Cidara Therapeutics and gave the company a “market outperform” rating in a report on Friday, October 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Cidara Therapeutics in a research report on Wednesday, October 8th. Citigroup reissued a “market outperform” rating on shares of Cidara Therapeutics in a research note on Tuesday, October 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $150.00 target price on shares of Cidara Therapeutics in a research note on Tuesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $151.33.

Insider Buying and Selling

In other Cidara Therapeutics news, insider Nicole Negar Davarpanah sold 474 shares of the company’s stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $62.86, for a total value of $29,795.64. Following the transaction, the insider directly owned 31,418 shares of the company’s stock, valued at $1,974,935.48. This represents a 1.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.64% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cidara Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CDTX. Commodore Capital LP acquired a new stake in Cidara Therapeutics in the second quarter valued at approximately $57,234,000. Soleus Capital Management L.P. acquired a new position in shares of Cidara Therapeutics during the 2nd quarter worth $22,544,000. First Light Asset Management LLC bought a new position in shares of Cidara Therapeutics during the 2nd quarter valued at $8,798,000. Invesco Ltd. acquired a new stake in shares of Cidara Therapeutics in the 2nd quarter valued at $6,110,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Cidara Therapeutics in the 2nd quarter valued at $5,709,000. Institutional investors and hedge funds own 35.82% of the company’s stock.

About Cidara Therapeutics

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.